Medgenics Inc Medgenics to Host Business Update Conference Call (1200S)
04 Noviembre 2013 - 8:00AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 1200S
Medgenics Inc
04 November 2013
Press Release 4 November 2013
Medgenics to Host Business Update Conference Call on Friday,
November 8th at 8:30 a.m. Eastern time
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) ("the
Company"), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces that the Company will host an
investment community conference call on Friday, November 8, 2013
beginning at 8:30 a.m. Eastern time to provide a business update
and to answer questions. Shareholders and other interested parties
may participate in the conference call by dialing 877-664-6134
(from within the U.S.) or 702-495-1913 (from outside the U.S.) or
1-809-457-877 (toll-free from Israel) and entering passcode
94707205. The call also will be broadcast live on the internet at
www.streetevents.com, www.earnings.com and www.medgenics.com.
A replay of the conference call will be accessible two hours
after its completion through November 14, 2013 by dialing (855)
859-2056 (from within the U.S.) or (404) 537-3406 (from outside the
U.S.) and entering passcode 94707205. The call will also be
archived for 90 days at www.streetevents.com, www.earnings.com and
www.medgenics.com.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Contacts:
Medgenics, Inc.
John Leaman, CFO
john.leaman@medgenics.com
LHA
Anne Marie Fields,
afields@lhai.com
@LHA_IR_PR 212-838-3777
Abchurch Communications
Joanne Shears / Jamie Hooper
/ Harriet Rae
harriet.rae@abchurch-group.com +44 207 398 7718
Oriel Securities (NOMAD & Joint
Broker)
Jonathan Senior / Giles Balleny +44 207 710 7617
SVS Securities plc (Joint Broker)
Alex Brearley +44 203 700 0100
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCNKQDQDBDDCDK
Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024